Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 5/20 | 0.66 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.66 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.66 |
| ▸ | HTR3B | O95264 | 3/20 | 0.66 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.66 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.66 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.66 |
| ▸ | DRD2 | P14416 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | DRD3 | P35462 | 1/20 | 0.66 |
| ▸ | HTR6 | P50406 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | HTR7 | P34969 | 4/20 | 0.59 |
| ▸ | HTR1A | P08908 | 3/20 | 0.58 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8700015 | 0.90 | HTR3A (0.58) | HTR3AADRB1HTR3EHTR3BHTR3D | |
| SCHEMBL31651649 | 0.88 | HTR3A (0.57) | HTR3AADRB1HTR3EHTR3BHTR3D | |
| SCHEMBL31167417 | 0.88 | ADRB1 (0.57) | HTR3AADRB1HTR3EHTR3BHTR3D | |
| SCHEMBL2541843 | 0.88 | HTR3A (0.57) | HTR3AADRB1HTR3EHTR3BHTR3D | |
| SCHEMBL31167421 | 0.88 | ADRB1 (0.57) | HTR3AADRB1HTR3EHTR3BHTR3D | |
| SCHEMBL9523382 | 0.88 | HTR3A (0.57) | HTR3AADRB1HTR3EHTR3BHTR3D | |
| SCHEMBL31652078 | 0.87 | HTR1A (0.61) | HTR3AADRB1HTR3EHTR3BHTR3D | |
| SCHEMBL14355748 | 0.82 | ALDH1A1 (0.51) | HTR3AADRB1HTR3EHTR3BHTR3D | |
| SCHEMBL379 | 0.79 | HTR3A (1.00) | HTR3AADRB1HTR3EHTR3BHTR3D | |
| SCHEMBL29396943 | 0.79 | HTR3A (1.00) | HTR3AADRB1HTR3EHTR3BHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| EP-3363645-B1 | PRETREATMENT OF UV CURED INK UNDER-LAYERS | XEROX CORP (US) | 2019-10-23 | — | — | EP | disclosed |
| CN-104177923-B | Ultraviolet curing water-based ink, print cartridge, recording device and recording method | 富士施乐株式会社 | 2019-01-29 | — | — | CN | disclosed |
| EP-3375621-A2 | TWO COMPONENT INK JETTABLE PRIMER AND INCORPORATION OF ADHESION PROMOTER TO THE INK FOR PRINTING ONTO 3D OBJECTS | Xerox Corporation (US) | 2018-09-19 | — | — | EP | disclosed |
| EP-3363645-A1 | PRETREATMENT OF UV CURED INK UNDER-LAYERS | Xerox Corporation (US) | 2018-08-22 | — | — | EP | disclosed |
| US-10005294-B1 | Two component ink jettable primer and incorporation of adhesion promoter to the ink for printing onto 3D objects | XEROX CORPORATION (US) | 2018-06-26 | — | — | US | disclosed |
| US-9969185-B1 | Pretreatment of UV cured ink under-layers | XEROX CORPORATION (US) | 2018-05-15 | — | — | US | disclosed |
| US-9498976-B2 | Ultraviolet-curable aqueous ink, ink cartridge, recording apparatus and recording method | FUJI XEROX CO., LTD. (JP) | 2016-11-22 | — | — | US | disclosed |
| US-9056999-B2 | Ultraviolet-curable aqueous ink, ink cartridge, recording apparatus and recording method | FUJI XEROX CO., LTD. (JP) | 2015-06-16 | — | — | US | disclosed |
| CN-104231742-A | ULTRAVIOLET-CURABLE AQUEOUS INK, INK CARTRIDGE, RECORDING APPARATUS AND RECORDING METHOD | FUJI XEROX CO LTD | 2014-12-24 | — | — | CN | disclosed |
| US-7468369-B2 | Sulfonyl pyrrolidines, method for producing the same and their use as drugs | SANOFI-AVENTIS (FR) | 2008-12-23 | — | — | US | disclosed |
| US-20080045540-A1 | SULFONYL PYRROLIDINES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| EP-1836180-A2 | SULFONYL PYRROLIDINES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS | sanofi-aventis (FR) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006072393-A2 | SULFONYL PYRROLIDINES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS | SANOFI-AVENTIS (DE) | 2006-07-13 | — | — | WO | disclosed |
| EP-0563345-B1 | NOVEL 4-ARYLPIPERAZINES AND 4-ARYLPIPERIDINES | MCNEILAB INC (US) | 2002-07-03 | — | — | EP | disclosed |
| US-5569659-A | ANTIPSYCHOTIC AGENT | MCNEILAB, INC. (US) | 1996-10-29 | — | — | US | disclosed |
| EP-0563345-A1 | NOVEL 4-ARYLPIPERAZINES AND 4-ARYLPIPERIDINES | MCNEILAB, INC. (US) | 1993-10-06 | — | — | EP | disclosed |
| EP-0562049-A1 | NOVEL 4-ARYLPIPERAZINES AND 4-ARYLPIPERIDINES | MCNEILAB, INC. (US) | 1993-09-29 | — | — | EP | disclosed |
| WO-1993004682-A1 | NOVEL 4-ARYLPIPERAZINES AND 4-ARYLPIPERIDINES | MCNEILAB, INC. (US) | 1993-03-18 | — | — | WO | disclosed |
| WO-1993004684-A1 | NOVEL 4-ARYLPIPERAZINES AND 4-ARYLPIPERIDINES | MCNEILAB, INC. (US) | 1993-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045540-A1 | SULFONYL PYRROLIDINES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS | SLC5A1, SLC5A2, KCNJ1 | HTR3A 2464/4885ADRB1 1137/4885HTR3E 3673/4885 |
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | STAT6, STAT5B, STAT5A | HTR3A 4148/4885ADRB1 2760/4885HTR3E 2136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.